-
Cyclins and Cyclin Dependent Kinase – Review(Post)
Cell Cycle · KinasesCyclins and Cyclin-Dependent Kinases: Regulation, Substrates and Mitotic ControlCDKs are inactive on their own. They require a cyclin partner, and because cyclin levels rise and fa
Citations(Page) The Neural Shield: How Cancer-Induced Nerve Injury Drives Immunotherapy Resistance(Post)For years, our understanding of cancer focused primarily on the tumor cells themselves and the immune system's response. However, a groundbreaking wave of research is revealing a startling truth: ner
Cabiralizumab: Unlocking the Potential of Anti-CSF1R Therapy(Post)What You Need to Know About CabiralizumabWhat is Cabiralizumab?Cabiralizumab is a monoclonal antibody targeting the colony-stimulating factor-1 receptor (CSF1R), developed for treating c
Bevacizumab: Mechanism, Clinical Applications, and Biosimilar Insights(Post)Quick Facts About BevacizumabWhat is Bevacizumab?Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis (the formation of ne
Avdoralimab: Exploring Its Role in Immunotherapy and Biosimilar Advancements(Post)Quick Facts About AvdoralimabWhat is Avdoralimab?Avdoralimab is a monoclonal antibody targeting C5aR1, playing a crucial role in modulating immune response and inflammation.What is the m
Eldelumab: Unlocking the Potential of Anti-TNFSF14 in Inflammatory Diseases(Post)Quick Facts About EldelumabWhat is Eldelumab?Eldelumab is a monoclonal antibody targeting TNFSF14 (LIGHT), a key regulator in immune system signaling, with potential applications in infl
Durvalumab: Advancing Immunotherapy in Cancer Treatment(Post)Quick Facts About DurvalumabWhat is Durvalumab?Durvalumab (Imfinzi) is a PD-L1 checkpoint inhibitor used in immunotherapy to treat various cancers, including non-small cell lung cancer (
Begelomab: Mechanism of Action, Clinical Applications & Biosimilars(Post)Quick Facts About BegelomabWhat is Begelomab?Begelomab is a monoclonal antibody that targets CD26, a key molecule involved in immune regulation. It has been studied for its potential app
Guselkumab: Advancing Psoriasis and Autoimmune Disease Research Through IL-23 Targeting(Post)Quick Facts About GuselkumabWhat is Guselkumab?Guselkumab is a biologic therapy that selectively targets the p19 subunit of interleukin-23 (IL-23), playing a critical role in inflammator
CD52 Expression(Post)What is CD52? Cluster Of Differentiation 52 (CD52) is a highly expressed membrane glycoprotein which is present on the surface of immune cell
Resources(Page) Crizanlizumab: A Comprehensive Overview of Its Role in Sickle Cell Disease and Ongoing Research(Post)Quick Facts About CrizanlizumabWhat is Crizanlizumab?Crizanlizumab is a monoclonal antibody used to treat sickle cell disease by targeting P-selectin, a protein involved in inflammation
Influenza Hemagglutinin (HA) Subtypes and Flu Virus Strains: What You Need to Know(Post)The flu is a highly contagious virus that affects the respiratory system. It can cause fever, muscle aches, and coughing. In some cases, it can lead to more serious health complicati
Tocilizumab: Advancing Therapeutics and Research with Biosimilars(Post)What You Need to Know About TocilizumabWhat is Tocilizumab?Tocilizumab is a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, widely used for managing autoimmune and in
Relatlimab: Unlocking the Potential of LAG-3 Inhibition in Cancer Research(Post)Quick Facts About RelatlimabWhat is Relatlimab?Relatlimab is a monoclonal antibody that targets LAG-3 (Lymphocyte Activation Gene-3), a key immune checkpoint involved in T-cell regulatio
Imalumab: Unveiling Its Mechanism, Clinical Potential, and Biosimilar Advancements(Post)What You Need to Know About ImalumabWhat is Imalumab?Imalumab is a monoclonal antibody targeting macrophage migration inhibitory factor (MIF), a key regulator of inflammation and immune
Your Th2 Phenotype Might Not Be a T Cell(Post)If your knockout showed a type 2 phenotype and you attributed it to Th2 cells, there is a reasonable chance you were looking at something else. Innate lymphoid cells run T-bet, GATA3 and RORγt — not
PD-1/PD-L1 Checkpoint Signalling: Pathway, Function and Assays(Post)PD-1 does not switch a T cell off; it moves the threshold. Engagement of PD-1 by PD-L1 recruits a single phosphatase into the immunological synapse, and that one recruitment event is enough to collap
CD80: Amplifying Immune Activation Through Co-Stimulatory Pathways(Post)Introduction to CD80 and Its Role in Immune Activation CD80 is a critical immune checkpoint molecule that plays an essential role in T cell activation through co-stimulatory pathways. Exp